{"id":"W3180369792","doi":"10.1007/s13311-021-01088-5","title":"Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis","year":2021,"lang":"en","type":"article","venue":"Neurotherapeutics","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Institute of Neurological Disorders and Stroke; Fonds de Recherche du Québec - Santé; National Institute of General Medical Sciences; U.S. Department of Defense","keywords":"Experimental autoimmune encephalomyelitis; Neuroprotection; Neurodegeneration; Multiple sclerosis; Medicine; Agonist; Myelin oligodendrocyte glycoprotein; Encephalomyelitis; Inflammation; Immunology; Neuroscience; Receptor; Pharmacology; Biology; Internal medicine; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001691264,0.0002199809,0.0002649864,0.0001662232,0.0001600132,0.0002100358,0.0001856738,0.0003471715,0.0009020391],"category_scores_gemma":[0.00007590577,0.00005934256,0.0001510834,0.00009824844,0.000190571,0.0002579985,0.0001304329,0.0006018973,0.0001983093],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001435196,"about_ca_system_score_gemma":0.0001939544,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001533467,"about_ca_topic_score_gemma":0.0003519894,"domain_scores_codex":[0.9999443,0.00001663807,0.000005327405,0.000006265286,0.000007477926,0.00001992768],"domain_scores_gemma":[0.9999762,0.000006204289,0.000005001305,0.000002353268,0.000002051925,0.000008205094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003867758,0.0008658878,0.0004386689,0.0003692844,0.00003150697,0.0009390258,0.000055517,0.0007402274,0.9335884,0.001418348,0.0006910472,0.05699423],"study_design_scores_gemma":[0.003380542,0.03161092,0.006928336,0.0001315406,0.0002487844,0.004193931,0.0002025249,0.003772546,0.9180512,0.001189281,0.03023819,0.00005223544],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800616,0.01249964,0.002132113,0.0006334539,0.0002030901,0.00006683107,0.0001300579,0.0000691878,0.004203937],"genre_scores_gemma":[0.9897316,0.005943919,0.001915808,0.0001887078,0.000051253,0.00007420342,0.0001510362,0.000005195856,0.001938285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009020391,"threshold_uncertainty_score":0.003017604,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01909608177483972,"score_gpt":0.2677871437255566,"score_spread":0.2486910619507169,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}